# Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

> **NCT07102628** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 300 (estimated)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** Placebo
- **DRUG:** Inclisiran

## Key facts

- **NCT ID:** NCT07102628
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-03
- **Primary completion:** 2027-02-11
- **Final completion:** 2027-02-11
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07102628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07102628, "Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07102628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*